Download MendeleySmall molecules that inhibit TNF signalling by stabilising an asymmetric form of the trimer.
O'Connell, J., Porter, J., Kroeplien, B., Norman, T., Rapecki, S., Davis, R., McMillan, D., Arakaki, T., Burgin, A., Fox Iii, D., Ceska, T., Lecomte, F., Maloney, A., Vugler, A., Carrington, B., Cossins, B.P., Bourne, T., Lawson, A.(2019) Nat Commun 10: 5795-5795
- PubMed: 31857588
- DOI: https://doi.org/10.1038/s41467-019-13616-1
- Primary Citation of Related Structures:
6OOY, 6OOZ, 6OP0 - PubMed Abstract:
Tumour necrosis factor (TNF) is a cytokine belonging to a family of trimeric proteins; it has been shown to be a key mediator in autoimmune diseases such as rheumatoid arthritis and Crohn's disease. While TNF is the target of several successful biologic drugs, attempts to design small molecule therapies directed to this cytokine have not led to approved products. Here we report the discovery of potent small molecule inhibitors of TNF that stabilise an asymmetrical form of the soluble TNF trimer, compromising signalling and inhibiting the functions of TNF in vitro and in vivo. This discovery paves the way for a class of small molecule drugs capable of modulating TNF function by stabilising a naturally sampled, receptor-incompetent conformation of TNF. Furthermore, this approach may prove to be a more general mechanism for inhibiting protein-protein interactions.
Organizational Affiliation:
UCB Pharma, Slough, SL1 3WE, UK. james.oconnell@ucb.com.
